<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636138</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00145686</org_study_id>
    <nct_id>NCT04636138</nct_id>
  </id_info>
  <brief_title>Pharmacogenomic Modulators of Impaired Exercise Adaptation in Statin Users</brief_title>
  <official_title>Pharmacogenomic Modulators of Impaired Exercise Adaptation in Statin Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HMG-CoA reductase inhibitors (statins) have beneficial effects (prevent stroke, heart attack)&#xD;
      but also some bad ones (block some good effects of exercise). Individuals have genetic&#xD;
      variations in proteins that metabolize/transport statins. We hypothesize that these&#xD;
      variations modulate the relationship between statin use and lack of benefit from exercise. We&#xD;
      will test this by having statin-users do supervised exercise for 6 weeks, measuring the&#xD;
      cardiorespiratory fitness before/after and correlating this to genetic variations present in&#xD;
      the patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak oxygen consumption (VO2max)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change pre/post intervention; compared with genomic variants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting heart rate</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting systolic blood pressure</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>HMG-CoA Reductase Inhibitor Toxicity</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Patients will exercise on a treadmill three times weekly at approximately 60% VO2max for 30 minutes (week one) followed by 45 minutes (week two and thereafter) for a total of 6 seeks.</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: We will study English-speaking adults (aged 35-65 years) who are&#xD;
        overweight or obese (body-mass index [BMI] 25-43), currently taking high-dose atorvastatin&#xD;
        (80mg once daily) for primary prevention of cardiovascular disease and/or stroke, are&#xD;
        sedentary (&lt;30 minutes of structured exercise weekly), willing to participate in supervised&#xD;
        exercise three times weekly and to not make intentional changes to their diet during the&#xD;
        study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        We will exclude patients who (a) smoke, (b) are pregnant or breastfeeding, (c) use other&#xD;
        medications that affect lipid metabolism (e.g. fibric acid, fish oil), (d) who are markedly&#xD;
        functional debilitated and unable to exert 4 metabolic equivalents (METs) of energy (e.g.&#xD;
        unable to climb a flight of stairs without stopping), or (e) who have been advised by a&#xD;
        physician to avoid exercise due to comorbid serious cardiovascular disease, (f)&#xD;
        uncontrolled diabetes (A1c &gt; 8), uncontrolled thyroid disease, HIV/AIDS, cancer, (g)&#xD;
        history of myocardial infarction or stroke, or (h) history of statin-induced myopathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J Parente, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel J Parente, MD PhD</last_name>
    <phone>9139458054</phone>
    <email>dparente@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel J Parente, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel J Parente, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Billinger, PhD PT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

